CoChat
Cited by 244

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

Open access
Darb-Esfahani, Silvia, Kunze, Catarina Alisa, Kulbe, Hagen, Sehouli, Jalid, Wienert, Stephan, Lindner, Judith, Budczies, Jan, Bockmayr, Michael, Dietel, Manfred, Denkert, Carsten, Braicu, Ioana, Jöhrens, Korinna · 2016 · Oncotarget

Abstract

// Silvia Darb-Esfahani 1,2,* , Catarina Alisa Kunze 1,* , Hagen Kulbe 2,3 , Jalid Sehouli 2,3 , Stephan Wienert 1,4 , Judith Lindner 1 , Jan Budczies 1 , Michael Bockmayr 1 , Manfred Dietel 1 , Carsten Denkert 1,2 , Ioana Braicu 2,3 and Korinna Jöhrens 1 1 Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany 2 Tumorbank Ovarian Cancer Network, Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany 3 Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany 4 VM Scope GmbH, Berlin, Germany * These authors have contributed equally to the work Correspondence to: Silvia Darb-Esfahani, email: // Keywords : high grade serous carcinoma, ovarian, PD-1, PD-L1, tumor-infiltrating lymphocytes Received : June 12, 2015 Accepted : November 15, 2015 Published : November 29, 2015 Abstract Aims: Antibodies targeting the checkpoint molecules programmed cell death 1 (PD-1) and its ligand PD-L1 are emerging cancer therapeutics. We systematically investigated PD-1 and PD-L1 expression patterns in the poor-prognosis tumor entity high-grade serous ovarian carcinoma. Methods: PD-1 and PD-L1 protein expression was determined by immunohistochemistry on tissue microarrays from 215 primary cancers both in cancer cells and in tumor-infiltrating lymphocytes (TILs). mRNA expression was measured by quantitative reverse transcription PCR. An in silico validation of mRNA data was performed in The Cancer Genome Atlas (TCGA) dataset. Results: PD-1 and PD-L1 expression in cancer cells, CD3+, PD-1+, and PD-L1+ TILs densities as well as PD-1 and PD-L1 mRNA levels were positive prognostic factors for progression-free (PFS) and overall survival (OS), with all factors being significant for PFS ( p < 0.035 each), and most being significant for OS. Most factors also had prognostic value that was independent from age, stage, and residual tumor. Moreover, high PD-1+ TILs as well as PD-L1+ TILs densities added prognostic value to CD3+TILs (PD-1+: p = 0.002,; PD-L1+: p = 0.002). The significant positive prognostic impact of PD-1 and PD-L1 mRNA expression could be reproduced in the TCGA gene expression datasets ( p = 0.02 and p < 0.0001, respectively). Conclusions: Despite their reported immune-modulatory function, high PD-1 and PD-L1 levels are indicators of a favorable prognosis in ovarian cancer. Our data indicate that PD-1 and PD-L1 molecules are biologically relevant regulators of the immune response in high-grade serous ovarian carcinoma, which is an argument for the evaluation of immune checkpoint inhibiting drugs in this tumor entity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6429

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 244

Metadata

Authors
Darb-Esfahani, S., Kunze, C. A., Kulbe, H., Sehouli, J., Wienert, S., Lindner, J., Budczies, J., Bockmayr, M., Dietel, M., Denkert, C., Braicu, I., & Jöhrens, K.
Venue
Oncotarget
Published
2015-11-29
Volume
7
Issue
2
Pages
1486-1499
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2186690436
Cited by
244
References
10
FWCI
12.48
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.